Pfizer adds shifts, invests resources to cope with surge in demand for syphilis treatment
As Pfizer continues to grapple with increased demand for its antibiotic Bicillin, experts worry shortages may stoke the worsening syphilis epidemic in the US.
The pharma giant announced last month that it anticipates shortages for certain Bicillin L-A and Bicillin C-R prefilled syringes “due to an increase in syphilis infection rates as well as competitive shortages.” Bicillin is a long-acting form of penicillin commonly used to treat syphilis and is the only drug currently recommended to treat pregnant women with the sexually transmitted infection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
